Evaluating azetukalner for treating major depressive disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 clinical trial is a multicenter, randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of azetukalner as a monotherapy in adults diagnosed with Major Depressive Disorder (MDD). Participants will be randomly assigned to receive either azetukalner or a placebo, and their responses will be monitored over the course of the study. The trial aims to provide robust data on the potential benefits of azetukalner in alleviating symptoms of depression.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Adults ≥18 and ≤74 years of age and experienced their first major depressive episode (MDE) prior to 50 years of age
* Body Mass Index (BMI) ≤40 kg/m2
* Meets the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revised (DSM-5-TR) criteria for current major depressive disorder and is currently in an MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI)
* Participant's current MDE has a duration of ≥6 weeks and ≤24 months.

Key Exclusion Criteria:

* Participant has a primary diagnosis of a mood disorder other than MDD.
* Participant has a history of any of the following: MDD with psychotic or catatonic features; MDD with mixed features; Bipolar I or II disorder; Obsessive-compulsive disorder; Schizophrenia, primary thought disorder, or other psychotic disorder.
* Participant has a current diagnosis of any of the following: MDD with seasonal pattern; Depression with peripartum or perimenopausal onset; Post traumatic stress disorder; Antisocial or borderline personality disorder (or presence of clinically significant borderline personality traits); Panic disorder and/or agoraphobia; ADHD treated with a psychostimulant, diagnosed during the current MDE, or with unstable symptoms, as judged by the investigator.
* Participant has a substance (excluding tobacco) or alcohol use disorder within the 12 months prior to screening.
* Participant has had an active suicidal plan/intent within the 6 months prior to screening, presence of suicidal behavior in the last 2 years, or \>1 suicide attempt \>24 years of age.
* Participant has a history of non-suicidal self-harm behavior in the 12 months prior to screening.
* Participant has used antidepressants or other prohibited medications (including benzodiazepines), within the 2 weeks (4 weeks for fluoxetine) or within a period less than 5 times the drug's half-life, whichever is longer, prior to randomization.
* Participant has a history of non-response to ≥2 antidepressant drugs of adequate dose and duration in the current MDE as determined by the Antidepressant Treatment Response Questionnaire (ATRQ).
* Participants with medical conditions that may interfere with the purpose or conduct of the study
* Participant is pregnant, breastfeeding, or planning to become pregnant.

Where it's running

• IMA Clinical Research Phoenix
  Phoenix, Arizona, United States Recruiting
• Woodland International Research Group
  Little Rock, Arkansas, United States Recruiting
• Woodland Research Northwest
  Rogers, Arkansas, United States Recruiting
• Behavioral Research Specialists, Llc
  Glendale, California, United States Recruiting
• Marvel Clinical Research
  Huntington Beach, California, United States Recruiting
• Irvine Clinical Research
  Irvine, California, United States Recruiting

Study contacts

• Study coordinator: Xenon Medical Affairs
• Email: XenonCares@xenon-pharma.com
• Phone: 1-604-484-3300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dupilumab for Major Depressive Disorder

  This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07908563

• Accelerated vs Standard iTBS for Major Depression

  This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.

  Recruiting Military Hospital 175 · Ho Chi Minh City · NCT07768397

• Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD

  This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.

  Recruiting Phase 3 Khyber Medical University Peshawar · Islamabad, Capital and 2 other locations · NCT07703722

• Magnesium Bisglycinate Added to Your Depression Treatment

  This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.

  Recruiting All India Institute of Medical Sciences, Bhubaneswar · Bhubaneswar, Odisha · NCT07633080

• Motif XCS System for treatment-resistant depression

  This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.

  Recruiting at 4 sites Motif Neurotech, Inc. · Atlanta, Georgia and 3 other locations · NCT07594483

• A Phase 3 test of DT120 for major depressive disorder

  DT120 is tested against placebo in adults with major depressive disorder to see if it can help reduce depressive symptoms.

  Recruiting at 23 sites Phase 3 Definium Therapeutics US, Inc. · Little Rock, Arkansas and 25 other locations · NCT07592689

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.